Pompe disease is an autosomal recessive disorder, caused by defi ciency of acid alpha-glucosidase (GAA), which results in lysosomal accumulation of glycogen in multiple organs, with prominent involvement of heart and skeletal muscle. Early diagnosis is highly important, since prompt initiation of enzyme replacement therapy may improve morbidity and mortality.
RESULTS
Assay for GAA enzyme was successfully achieved with acceptable statistics.
The entire procedure fi ts into a 60-h cycle, including data analysis. To ensure the quality management system of our testing performance for each run, appropriate blanks, a series of calibration and at three levels (low, medium, and high) of control sample received from the Centers for Disease Control and Prevention (CDC), were included. We established our own references which were similar to the CDC references. Data from 5,030 anonymous newborn DBS samples showed an approximate bell-shaped distribution of enzymatic activities. Mean values ± two standard deviations of 12.46 (±5.37), μmol/h/L blood were calculated. Abnormal GAA activity (less than 2 μmol/h/L blood) was established and was similar to the published data. Since the introduction of this technique, we have studied 76 DBS samples from patients presenting with muscle weakness, respiratory insufficiency, and/or cardiomyopathy that were referred to our metabolic laboratory. Eight new infantile Pompe patients were diagnosed with the mean activity of 0.79 (±0.57) μmol/ h/L blood. The underlying mutations were confi rmed in all patients.
CONCLUSION
In our experience, the LC-MS/MS GAA activity assay provides a rapid and reliable fi rst-tier test for early diagnosis of patients suspected of having Pompe disease for timely treatment. 
